Study Details

Back to Search Results

A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 with Either Docetaxel or Paclitaxel in Patients with Advanced Non-hematologic Malignancies

Terminated/Withdrawn
The study has stopped early and will not start again. Participants were not enrolled (for withdrawn studies), however if participants were enrolled, they are no longer being examined or treated.

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT01705483

Astellas Study ID

The unique identification code given by the study sponsor.

9853-CL-0101

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Other, Cancer - Other

Phase

These clinical trials are usually the first time an experimental treatment is studied in a small group of people.

Phase 1

Age

18 years - N/A

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Aug 2012 - Jun 2014

Masking

None (Open Label)

Enrollment number

21

A Phase 1, Multicenter, Open-Label, Dose Escalation Study of ASP9853 in Combination with Either Docetaxel or Paclitaxel in Subjects with Advanced Non-hematologic Malignancies

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 with Either Docetaxel or Paclitaxel in Patients with Advanced Non-hematologic Malignancies? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Sarah Cannon Research Institute

Nashville, United States, 37203

Barbara Ann Karmanos Cancer Center

Detriot, United States, 48201

Beth Israel Deaconess Medical Center

Boston, United States, 02215

Dana Farber Cancer Institute

Boston, United States, 02215

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo